Clinical trials: Neoadjuvant Melanoma
Resectable Mucosal Melanoma
Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal Melanoma
The primary objective of this study is to evaluate the pathological response rate of neoadjuvant therapy with paclitaxel polymersomes for injection combined with carboplatin and adebrelimab in patients with resectable mucosal…
- Trial name
- NCT07336979
- Testing
- Paclitaxel Polymersomes Combined with Carboplatin and Adebelimab, Radical Surgery
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Malignant Melanoma Stage III
Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma
This is an international (Australia, Europe, and USA) open-label two-arm randomized phase 3 trial including 420 stage III (≤3 resectable in-transit metastases allowed) cutaneous or unknown primary melanoma patients.
- Trial name
- NADINA (NCT04949113)
- Testing
- Neoadjuvant ipilimumab + nivolumab, Adjuvant nivolumab
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 423 people
- Sponsor
- The Netherlands Cancer Institute
Stage IIIB Melanoma, Stage IIIC Melanoma
RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery
This pilot phase II trial is studying how well RO4929097 works in treating patients with stage III, or stage IV melanoma that can be removed by surgery.
- Conditions
- Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
- Trial name
- NCT01216787
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, pharmacological study, therapeutic conventional surgery
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Cutaneous Melanoma, Mucosal Melanoma
Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
This clinical trial is for patients with stage 3 cutaneous melanoma and patients with mucosal melanoma who are able to have surgery to remove all tumour deposits.
- Trial name
- Neo IRENIE (NCT06999980)
- Testing
- Ipilimumab 3mg/kg and nivolumab 1mg/kg, Ipilimumab 1mg/kg Nivolumab 480mg and relatlimab 160mg, Nivolumab 480mg and relatlimab 160mg
- Where
- Australia
- Volunteers
- 494 people
- Sponsor
- Melanoma Institute Australia
Acral Melanoma
Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma
Acral melanoma is a melanoma that affects acral areas of the skin, which is the most prevalent site of melanoma in non-Caucasians.Data in this subgroup is scarce.This study is to evalueate the efficiency and safety of Neoadjuvant…
- Trial name
- NCT04331093
- Testing
- SHR-1210+Apatinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Di Wu
Melanoma
Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma
This is an open label, single centre, phase II study of neoadjuvant drug treatment with dabrafenib + trametinib in patients with resectable American Joint Committee on Cancer (AJCC) Stage IIIB-C BRAF V600 mutation positive…
- Trial name
- Neo Combi (NCT01972347)
- Testing
- Dabrafenib, Trametinib
- Where
- Australia
- Volunteers
- 35 people
- Sponsor
- Melanoma Institute Australia
Melanoma
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
To Determine the feasibility, compliance and adherence to PreFED intervention in resectable melanoma patients initiating neoadjuvant Ipi/Nivo.
- Trial name
- NCT06548789
- Testing
- Prebiotic Xnack Packouts
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma Stage IIIB, Melanoma Stage IIIC
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C/D melanoma…
- Conditions
- Melanoma Stage IIIB, Melanoma Stage IIIC, Melanoma Stage IIID
- Trial name
- NeoDREAM (NCT03567889)
- Testing
- Daromun, Surgery, Adjuvant therapy
- Where
- 37 sites in United States, Spain and 1 more
- Volunteers
- 186 people
- Sponsor
- Philogen S.p.A.
Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin
Intratumoral PH-762 for Cutaneous Carcinoma
The goal of this clinical trial is to evaluate the safety and tolerability of intratumoral injections of PH-762 in squamous cell carcinoma, melanoma, or Merkel cell carcinomas of the skin, to understand what the body does to the…
- Conditions
- Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin, Merkel Cell Carcinoma of Skin
- Trial name
- NCT06014086
- Testing
- PH-762
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Phio Pharmaceuticals Inc.
Locoregional Metastases in Malignant Melanoma Stages IIIB/C
NAM-Trial: Multiferon in Malignant Melanoma
The current clinical trial shall clarify the efficacy, safety and biologic effects of neoadjuvant treatment with natural interferon-α (Multiferon) in patients with locoregional metastases of melanoma in stage IIIB/C.
- Trial name
- NCT01341158
- Testing
- human interferon-α
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- University Hospital Tuebingen
Stage IIIB-C Melanoma
ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma
Neoadjuvant Vemurafenib and Cobimetinib in BRAF V600 Mutant Stage IIIB-C Melanoma To evaluate the overall radiological complete response rate in patients with stage IIIB/C melanoma after 8 weeks of neoadjuvant vemurafenib and…
- Trial name
- NCT03005639
- Testing
- Vemurafenib and Cobimetinib
- Where
- United States
- Sponsor
- Inova Health Care Services
Melanoma
Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b
This study plans to to estimate the safety profile of the combination biotherapy regimen consisting of standard-dose interferon alpha-2b (HDI) and anti-PD1 monoclonal antibody, Pembrolizumab, for the neoadjuvant therapy of…
- Trial name
- NCT02339324
- Testing
- Pembrolizumab and high dose interferon alfa-2b (HDI)
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Yana Najjar